| abstract |
Compounds of the following general formula (I) andnpharmaceutically acceptable salts thereof.n n According to the present invention, compounds whichnantagonize the action of fibrinogen receptors and,ntherefore, have a high platelet aggregation-inhibitingnactivity, an in vivo stability against the cleavage withnproteotytic enzymes and an excellent bioavailability arenprovided, which are useful as agents for inhibitingnplatelet aggregation. The pharmaceutical preparationsncomprising the compounds as active ingredient are veryneffective for preventing platelet thrombosis,nthromboembolism and reocclusion during and afternthrombolytic therapy, and preventing platelet thrombosis,nthromboembolism and reocclusion after angioplasty ofncoronary and other arteries and after coronary arterynbypass procedures. These preparations are also be veryneffective for preventing unstable angina and myocardialninfraction, improving peripheral circulatory bloodstreamnand inhibiting blood coagulation during extracorporealncirculation. |